Prothena (PRTA) Q4 2025 earnings review
Revenue Evaporates as Strategy Shifts to Preservation
Prothena's FY25 results mark a painful transition following the mid-year discontinuation of its lead self-commercialization asset, birtamimab. Revenue collapsed from $135M in FY24 to just $9.7M in FY25, and Net Loss doubled to $244M. However, the company has aggressively pivoted to a 'hibernation' mode to preserve its $308M cash pile. With R&D expenses slashed and FY26 cash burn guided to a lean $50-55M, Prothena is now a pure-play holding company waiting for Roche, Novo Nordisk, and BMS to deliver on clinical milestones.
🐂 Bull Case
The aggressive cost-cutting is working. Cash burn is guided to drop from ~$164M in FY25 to just $50-55M in FY26. With $308M on hand, Prothena has bought itself roughly 5-6 years of runway to wait for partner data readouts without needing immediate dilution.
The pipeline is now de-risked financially. Roche initiated Phase 3 for prasinezumab (Parkinson's) and Novo Nordisk initiated Phase 3 for coramitug (ATTR-CM). These partners are funding the expensive late-stage development, with Prothena eligible for up to $105M in milestones in 2026 alone.
🐻 Bear Case
Q4 revenue was negligible ($21,000). The company has effectively ceased generating meaningful recurring revenue and is entirely dependent on lumpy, unpredictable milestone payments.
With the exit from birtamimab, Prothena is no longer the master of its own destiny. Timelines for the primary value drivers (Roche and Novo programs) are now dictated by partners, with primary completions pushed out to 2029.
⚖️ Verdict: 🔴
Neutral/Bearish. The rapid reduction in cash burn prevents a disaster rating, but the company is now a passive option on partner success rather than an active operator. The lack of near-term commercial catalysts makes this 'dead money' until clinical data matures.
Key Themes
Operational Shrinkage
The financials reflect a company dismantling its internal operations. R&D expenses in Q4 dropped to $14.6M from $50.2M a year ago (-71%), and G&A fell 25%. While necessary for survival, this confirms the abandonment of near-term internal growth ambitions following the birtamimab discontinuation in June 2025.
Partnered Pipeline Maturation
Despite the internal pullback, the external pipeline advanced. Roche started Phase 3 for prasinezumab (Parkinson's) and Novo Nordisk started Phase 3 for coramitug (ATTR-CM). Note the timeline: primary completion for both is expected in 2029. This creates a 3-4 year gap in major news flow.
Tax Asset Write-Down
Management recorded a $43.2M non-cash income tax expense to book a full valuation allowance against deferred tax assets. This is an accounting admission that the company does not expect to generate sufficient taxable income in the foreseeable future to utilize these assets.
2026 Milestone Potential
Guidance explicitly excludes potential milestone payments. Management noted the potential to earn up to $105M in 2026 related to Novo Nordisk (coramitug) and BMS (PRX019) advancements. If realized, this would double the current cash projected for year-end 2026.
Capital Return Flexibility
Shareholders approved a reduction in share capital to create distributable reserves. This technically allows for buybacks in 2026, though given the current cash preservation mode, aggressive buybacks seem unlikely unless milestone payments materialize.
Other KPIs
Stable. Down from $471M in FY24, but the burn rate has slowed significantly in H2 25. The restructuring in June 2025 stemmed the bleeding.
Decelerating. Collapsed 93% YoY from $135.2M in FY24. The prior year benefited from large license payments (BMS), whereas FY25 had minimal collaboration revenue.
Decelerating (Improving). Significant improvement compared to the average quarterly burn earlier in the year (~$40-50M), reflecting the full impact of cost-cutting measures.
Guidance
Decelerating. This represents a massive reduction (-68%) from the ~$164M burned in FY25. It confirms the shift to a low-cost holding company model.
Stable. Implies the company will retain a fortress balance sheet through the year. IMPORTANT: This figure excludes the potential $105M in clinical milestones.
Decelerating (Improving). A drastic improvement from the $244M loss in FY25, driven by the removal of restructuring charges and lower R&D spend.
Key Questions
Milestone Timing and Probability
The guidance mentions 'up to $105M' in potential milestones for 2026. Can you break down the specific clinical triggers for these payments and your internal probability weighting for achieving them this year?
PRX012 Strategy
With the focus shifting to partnered programs, what is the strategic future for the wholly-owned PRX012-TfR program? Is the goal to carry this internally or seek a partnership immediately upon preclinical data generation?
Capital Allocation
With the share capital reduction approved, under what specific conditions would you consider activating a share redemption program in 2026, versus preserving cash for pipeline longevity?